<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res Treat</journal-id><journal-title-group><journal-title>Breast Cancer Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39277550</article-id><article-id pub-id-type="pmc">PMC11785644</article-id>
<article-id pub-id-type="publisher-id">7491</article-id><article-id pub-id-type="doi">10.1007/s10549-024-07491-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Discordance between peritumoral and subareolar injections for mapping sentinel lymph nodes in the breast</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Situ</surname><given-names>Josephine</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Cameron</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jayathungage Don</surname><given-names>Tharanga D.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Suami</surname><given-names>Hiroo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>David K. V.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8146-1113</contrib-id><name><surname>Reynolds</surname><given-names>Hayley M.</given-names></name><address><email>Hayley.Reynolds@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03b94tp07</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution>Department of Engineering Science, </institution><institution>The University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03b94tp07</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution>Auckland Bioengineering Institute, </institution><institution>The University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01sf06y89</institution-id><institution-id institution-id-type="GRID">grid.1004.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 5405</institution-id><institution>Australian Lymphoedema Education Research and Treatment Program (ALERT), Department of Health Sciences, Faculty of Medicine, Health and Human Sciences, </institution><institution>Macquarie University, </institution></institution-wrap>Sydney, NSW Australia </aff><aff id="Aff4"><label>4</label>Alfred Nuclear Medicine and Ultrasound, Newtown, NSW Australia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Discipline of Child and Adolescent Health, Sydney Medical School, </institution><institution>University of Sydney, </institution></institution-wrap>Sydney, NSW Australia </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>209</volume><issue>2</issue><fpage>283</fpage><lpage>290</lpage><history><date date-type="received"><day>19</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Sentinel node biopsy (SNB) is a common staging tool for breast cancer. Initially, peritumoral (PT) injections were used, however subareolar (SA) injections were later introduced to simplify the technique. Controversy remains regarding whether PT and SA injections map the same sentinel lymph nodes (SLNs). This study aimed to determine whether the regional location of breast SLNs differs when using PT versus SA injections using a large dataset from a single institution.</p></sec><sec><title>Methods</title><p id="Par2">A total of 1035 patients who underwent breast SNB (PT injections: <italic>n</italic>&#x02009;=&#x02009;858 and SA injections: <italic>n</italic>&#x02009;=&#x02009;177) with lymphoscintigraphy and SPECT/CT were included. The identified SLN locations using SA injections were compared with those using PT injections. Differences in drainage proportions and odds ratios (ORs) for each clockface breast region and the whole breast were calculated using a two-proportion z-test and Fisher&#x02019;s Exact Test.</p></sec><sec><title>Results</title><p id="Par3">A higher proportion of internal mammary SLNs were identified using PT injections for the whole breast (0.30 versus 0.09) and for all breast regions, with all regions showing statistical significance except the upper outer quadrant. Similarly, ORs showed identification of internal mammary SLNs was significantly higher when using PT injections (4.35, 95% CI 2.53 to 7.95). There were no significant differences in identifying axillary SLNs between injection sites.</p></sec><sec><title>Conclusion</title><p id="Par4">This is the largest cohort study to compare the regional location of breast SLNs identified using PT injections versus SA injections. Discordance was shown in the SLNs identified between injection techniques, with PT injections more frequently identifying internal mammary SLNs.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10549-024-07491-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Peritumoral</kwd><kwd>Sentinel lymph node</kwd><kwd>Subareolar</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001505</institution-id><institution>Health Research Council of New Zealand</institution></institution-wrap></funding-source><award-id>20/017</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>University of Auckland</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by CAUL and its Member Institutions</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Lymphoscintigraphy (LS) and SPECT/CT is a standard imaging technique for mapping sentinel lymph nodes (SLNs) in breast cancer patients [<xref ref-type="bibr" rid="CR1">1</xref>]. However, there have been ongoing controversies regarding which radioactive tracer injection site accurately identifies the potential cancer-bearing lymph node [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Some support the use of superficial injections, which can involve subareolar (SA), periareolar, intradermal, and subdermal administration, while others support the use of deep injections, which include peritumoral (PT) or intratumoral delivery. Superficial SA injections have recently become popular for multiple reasons, including their fast SLN visualisation, lower use of resources as they do not require ultrasound guidance, and the fact that tracer at the injection site does not obscure axillary SLNs which can occur when using deep injection techniques [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Despite these benefits, SA injections are based on old anatomical studies which claim the SA plexus collects all lymph fluid from the breast [<xref ref-type="bibr" rid="CR4">4</xref>], which may not be accurate [<xref ref-type="bibr" rid="CR4">4</xref>]. Furthermore, clinical and anatomical studies have shown the breast is not a single ectodermal unit that always drains to the anteropectoral axillary lymph nodes as previously thought [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">To investigate the differences between superficial and deep injection techniques for breast SLN mapping, in 2014 Ahmed et al. [<xref ref-type="bibr" rid="CR2">2</xref>] and Sadeghi et al. [<xref ref-type="bibr" rid="CR8">8</xref>] carried out systematic reviews and meta analyses. Sadeghi et al. summarised 30 studies that assessed SLN locations of deep versus superficial injections in the same patients simultaneously or serially, while Ahmed et al. only analysed randomised controlled trials and cohort controlled studies which compared deep versus superficial injections, resulting in 13 studies for review. Analysis by Sadeghi et al. concluded there is fairly high and clinically acceptable concordance between superficial and deep injection methods, however they are clinically more successful if used together and can decrease the overall false negative rate. Meanwhile, Ahmed et al. concluded that superficial and deep injections are both suitable for identifying axillary SLNs, but identification of extra-axillary SLNs is significantly different between the techniques with deep injections identifying extra-axillary SLNs more often than superficial injections, particularly internal mammary SLNs [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par7">Many studies in the review by Ahmed et al. used blue dye, and only two compared PT and SA injections using radioactive tracer alone and SPECT/CT to localise breast SLNs [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. First, a multicentre study by Noushi et al. [<xref ref-type="bibr" rid="CR10">10</xref>] involving 39 patients who had sequential SA injections followed by PT injections, and second, a single-centre study by Uren et al. [<xref ref-type="bibr" rid="CR5">5</xref>] who analysed proportion differences in SLN locations from 737 patients undergoing PT injections and 75 patients having SA injections. Noushi et al. showed a high level of discordance between SA and PT injections of 56%, and reported that no patient showed identical SLNs in internal mammary nodes from both injection types. Meanwhile, when analysing drainage for SA injections relative to PT injections, Uren et al. observed a higher proportion of patients had drainage to the axillary level I anterior nodes and a significantly lower proportion had drainage to internal mammary nodes. More recently, Freebody et al. [<xref ref-type="bibr" rid="CR11">11</xref>] reported a study conducted in 2019 involving 123 patients who were given simultaneous PT, SA, and subcutaneous injections to identify breast SLNs. They were able to locate axillary SLNs 98% of the time and reported identifying internal mammary SLNs in 13% of their patients. Importantly, they found the different injection methods could identify different axillary SLNs. They concluded that multisite injections are an optimal way to identify axillary SLNs and that deep injections are required for internal mammary drainage to be reliably identified.</p><p id="Par8">Despite multiple studies reporting high discordance between SA and PT injections for extra-axillary SLN identification, SA injections continue to be used in recent clinical studies [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. To address the continued lack of consensus, we aimed to statistically analyse a large dataset from the same centre as Uren et al. [<xref ref-type="bibr" rid="CR6">6</xref>] to determine differences in the location of breast SLNs when using SA versus PT injections. This analysis advances further than previous studies by incorporating more refined breast region information and SLN localisations, including classification of the axilla into several subregions, due to the enhanced anatomical information from SPECT/CT. By analysing this data, we also aimed to improve understanding of lymphatic drainage of the breast.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patient data</title><p id="Par9">All patients who underwent breast LS and SPECT/CT at Alfred Nuclear Medicine and Ultrasound (ANMU) in Sydney, Australia between April 2018 and December 2022 were retrospectively identified. Patients who had past surgery or neoadjuvant therapy were excluded as past treatment can influence lymphatic drainage patterns [<xref ref-type="bibr" rid="CR1">1</xref>]. Patients with multifocal or large breast tumours (diameter&#x02009;&#x0003e;&#x02009;3&#x000a0;cm) were also excluded because it was unclear which PT injection site was the source of the lymph flow. SA injections were administered when the patient was scheduled for a prophylactic mastectomy, had ductal carcinoma in situ (DCIS), or tumours not visualised on ultrasound. There were 23 patients who had their SLNs mapped in both breasts, so to preserve data independence the data from only one breast was included in the statistical analysis by ordering patients by study date and alternately removing data from the left or right breast.</p><p id="Par10">A total of 1035 breast cancer patients were included in this study, with patient characteristics summarised in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. There were 858 patients (mean age 60.0&#x000a0;years) who received PT injections and 177 patients (mean age 53.7&#x000a0;years) who received SA injections. All patients who received SA injections were female, and the majority of patients who received PT injections were female (853, 99.4%) with only 5 male patients who had received PT injections included in the entire study cohort. The PT injection type was performed in the left breast for 448 (52.2%) of patients, and the right breast for the remaining 410 (47.8%) of patients. The SA injection type was performed in the left breast for 86 (48.6%) of patients and the right breast for 91 (51.4%) of patients.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristic</th><th align="left" colspan="2">Injection type</th></tr><tr><th align="left">Peritumoral</th><th align="left">Subareolar</th></tr></thead><tbody><tr><td align="left">Number of patients</td><td align="left">858</td><td align="left">177</td></tr><tr><td align="left">Age, mean (range)</td><td align="left">60.0 (25.5&#x02013;92.5)</td><td align="left">53.7 (27.8&#x02013;86.1)</td></tr><tr><td align="left">Sex</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Female</td><td align="left">853</td><td align="left">177</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left">5</td><td align="left">0</td></tr><tr><td align="left">Injection side</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Left</td><td align="left">448</td><td align="left">86</td></tr><tr><td align="left">&#x000a0;Right</td><td align="left">410</td><td align="left">91</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>LS and SPECT/CT imaging</title><p id="Par11">The LS and SPECT/CT procedure at ANMU has been described in detail previously [<xref ref-type="bibr" rid="CR6">6</xref>]. In brief, PT injections involved one to four injections (<sup>99m</sup>Tc-antimony sulphide colloid, each in 0.2&#x000a0;mL solution mixed with 0.2&#x000a0;mL 1% lignocaine) around the tumour under ultrasound guidance. For SA injections, two injections were delivered into the breast parenchyma under the areola from the upper outer breast quadrant. If drainage was poor, additional injections were made elsewhere in the breast parenchyma under the areola. The difference between PT and SA injection sites are illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Peritumoral (PT) and subareolar (SA) injection types for administering the radiocolloid tracer during LS and SPECT/CT</p></caption><graphic xlink:href="10549_2024_7491_Fig1_HTML" id="MO1"/></fig></p><p id="Par12">After the patient massaged the injection site for 5&#x000a0;min, LS was performed. If SLNs were identified on LS, SPECT/CT was acquired with the patient in the supine position. At the time of imaging, the nuclear medicine specialist manually annotated the position of SLNs on the SPECT images. The patient&#x02019;s primary tumour was classified using the 12 standard regions according to the clockface system (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The distance of the tumour from the nipple was also recorded and if it was 1&#x000a0;cm or less, the tumour was reclassified as being within a new retroareolar 0 o&#x02019;clock region. Patient SLNs were classified within one of 12 node fields, as described previously [<xref ref-type="bibr" rid="CR6">6</xref>]: axilla level I (anterior), axilla level I (central), axilla level I (lateral), axilla level I (posterior), axilla level I (interpectoral), axilla level II, axilla level III, internal mammary, supraclavicular, mediastinal, interval, and contralateral. Interval nodes were defined as SLNs between the injection site and a standard draining node field and were most commonly intercostal or intramammary nodes. Further anatomical details about each node field location are given in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Schematic showing the standard 12 clockface regions in the left breast and the retroareolar 0 o&#x02019;clock region</p></caption><graphic xlink:href="10549_2024_7491_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par13">The mapped SLN node field locations from each injection type were compared using a two-proportion z-test and Fisher&#x02019;s Exact Test. The SLN locations when using PT injections were first compared with SA injections in each breast region, and then again by combining the SLN locations from PT injections across the entire breast. The two-proportion z-test was only performed if, for a particular node field (and for both injection types), there were at least five patients with and without drainage to that node field [<xref ref-type="bibr" rid="CR15">15</xref>]. All p-values were Bonferroni-corrected [<xref ref-type="bibr" rid="CR16">16</xref>] by multiplying by the number of comparisons. All statistical analyses were conducted using the R Statistical Package [<xref ref-type="bibr" rid="CR17">17</xref>].</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par14">Table <xref rid="Tab2" ref-type="table">2</xref> shows results from the two-proportion z-test and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows results from Fisher&#x02019;s Exact Test. There were three node fields (mediastinal, contralateral, and supraclavicular) that were not tested as there was no drainage to these node fields with SA injections and rarely drainage with PT injections. An additional three node fields, axilla level I (lateral and interpectoral) and axilla level III could not be compared using the two-proportion z-test, as there were less than five SA patients with SLNs in these node fields. Combined axillary node fields had less than five SA patients without drainage, so these were not compared using the two-proportion z-test. Overall, almost all patients (99.1%) had an axillary sentinel node and 26.6% had an internal mammary sentinel node. Dual drainage to axillary and internal mammary nodes was common, involving 26.0% of patients. Patients with an internal mammary sentinel node but no axillary sentinel node was the smallest group, numbering 6 out of 1035 (0.6%) patients.
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Proportion of drainage to each node field, with PT injections separated into each clockface region including the retroareolar 0 o&#x02019;clock region. Significantly different drainage between PT injections and SA injections are shown in bold font (Bonferroni-corrected <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.05)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left" colspan="14">PT (breast region injection site, reflected to left side)</th></tr><tr><th align="left">Node field</th><th align="left">SA</th><th align="left">0</th><th align="left">1</th><th align="left">2</th><th align="left">3</th><th align="left">4</th><th align="left">5</th><th align="left">6</th><th align="left">7</th><th align="left">8</th><th align="left">9</th><th align="left">10</th><th align="left">11</th><th align="left">12</th><th align="left">All regions</th></tr><tr><th align="left"/><th align="left"><italic>N</italic>&#x02009;=&#x02009;177</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;108</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;83</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;198</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;93</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;56</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;41</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;31</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;24</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;23</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;22</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;56</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;60</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;63</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;858</th></tr></thead><tbody><tr><td align="left">Axilla level I (anterior)</td><td align="left">0.81</td><td align="left">0.78</td><td align="left">0.78</td><td align="left">0.82</td><td align="left">0.73</td><td align="left">0.79</td><td align="left">0.76</td><td align="left">0.65</td><td align="left">0.88</td><td align="left">0.83</td><td align="left">0.82</td><td align="left">0.75</td><td align="left">0.68</td><td align="left">0.73</td><td align="left">0.77</td></tr><tr><td align="left">Axilla level I (central)</td><td align="left">0.24</td><td align="left">0.33</td><td align="left">0.22</td><td align="left">0.30</td><td align="left">0.31</td><td align="left">0.32</td><td align="left">0.27</td><td align="left">0.32</td><td align="left">0.21</td><td align="left">0.30</td><td align="left">0.27</td><td align="left">0.29</td><td align="left">0.23</td><td align="left">0.33</td><td align="left">0.29</td></tr><tr><td align="left">Axilla level I (posterior)</td><td align="left">0.05</td><td align="left">0.08</td><td align="left">0.07</td><td align="left">0.11</td><td align="left">0.13</td><td align="left">0.13</td><td align="left">0.17</td><td align="left">0.16</td><td align="left">0.04</td><td align="left">0.09</td><td align="left">0.00</td><td align="left">0.05</td><td align="left">0.12</td><td align="left">0.06</td><td align="left">0.10</td></tr><tr><td align="left">Axilla level II</td><td align="left">0.06</td><td align="left">0.13</td><td align="left">0.11</td><td align="left">0.07</td><td align="left">0.08</td><td align="left">0.05</td><td align="left">0.07</td><td align="left">0.00</td><td align="left">0.08</td><td align="left">0.13</td><td align="left">0.05</td><td align="left">0.09</td><td align="left">0.07</td><td align="left">0.13</td><td align="left">0.08</td></tr><tr><td align="left">Internal mammary</td><td align="left">0.09</td><td align="left"><bold>0.33</bold></td><td align="left">0.22</td><td align="left">0.14</td><td align="left">0.14</td><td align="left"><bold>0.29</bold></td><td align="left"><bold>0.39</bold></td><td align="left"><bold>0.52</bold></td><td align="left"><bold>0.71</bold></td><td align="left"><bold>0.65</bold></td><td align="left"><bold>0.45</bold></td><td align="left"><bold>0.50</bold></td><td align="left"><bold>0.48</bold></td><td align="left">0.27</td><td align="left"><bold>0.30</bold></td></tr><tr><td align="left">Interval</td><td align="left">0.02</td><td align="left">0.12</td><td align="left">0.05</td><td align="left">0.08</td><td align="left">0.12</td><td align="left">0.07</td><td align="left"><bold>0.24</bold></td><td align="left">0.16</td><td align="left">0.17</td><td align="left">0.04</td><td align="left">0.05</td><td align="left">0.05</td><td align="left">0.10</td><td align="left">0.08</td><td align="left">0.10</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>PT odds (for a given breast region) divided by the SA odds, from Fisher&#x02019;s exact test, with significant results given in bold font with associated 95% CIs (Bonferroni-corrected <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.05)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="14">Odds Ratio (breast region injection site, reflected to left side)</th></tr><tr><th align="left">Node Field</th><th align="left">0</th><th align="left">1</th><th align="left">2</th><th align="left">3</th><th align="left">4</th><th align="left">5</th><th align="left">6</th><th align="left">7</th><th align="left">8</th><th align="left">9</th><th align="left">10</th><th align="left">11</th><th align="left">12</th><th align="left">All regions</th></tr><tr><th align="left"/><th align="left"><italic>N</italic>&#x02009;=&#x02009;108</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;83</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;198</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;93</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;56</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;41</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;31</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;24</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;23</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;22</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;56</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;60</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;63</th><th align="left"><italic>N</italic>&#x02009;=&#x02009;858</th></tr></thead><tbody><tr><td align="left">Axilla level I (anterior)</td><td align="left">0.83</td><td align="left">0.86</td><td align="left">1.11</td><td align="left">0.65</td><td align="left">0.87</td><td align="left">0.74</td><td align="left">0.43</td><td align="left">1.66</td><td align="left">1.13</td><td align="left">1.07</td><td align="left">0.71</td><td align="left">0.51</td><td align="left">0.64</td><td align="left">0.80</td></tr><tr><td align="left">Axilla level I (central)</td><td align="left">1.56</td><td align="left">0.86</td><td align="left">1.32</td><td align="left">1.41</td><td align="left">1.48</td><td align="left">1.14</td><td align="left">1.48</td><td align="left">0.82</td><td align="left">1.36</td><td align="left">1.17</td><td align="left">1.25</td><td align="left">0.95</td><td align="left">1.56</td><td align="left">1.28</td></tr><tr><td align="left">Axilla level I (lateral)</td><td align="left">0.54</td><td align="left">1.43</td><td align="left">0.59</td><td align="left">0.63</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">1.93</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">1.05</td><td align="left">0.98</td><td align="left">0.94</td><td align="left">0.68</td></tr><tr><td align="left">Axilla level I (posterior)</td><td align="left">1.92</td><td align="left">1.65</td><td align="left">2.64</td><td align="left">3.13</td><td align="left">3.02</td><td align="left">4.35</td><td align="left">4.06</td><td align="left">0.92</td><td align="left">2.01</td><td align="left">0.00</td><td align="left">1.20</td><td align="left">2.79</td><td align="left">1.43</td><td align="left">2.32</td></tr><tr><td align="left">Axilla level I (interpectoral)</td><td align="left">2.10</td><td align="left">1.62</td><td align="left">1.12</td><td align="left">0.95</td><td align="left">0.79</td><td align="left">2.22</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.73</td><td align="left">1.42</td><td align="left">1.09</td></tr><tr><td align="left"><italic>Axilla level I combined</italic></td><td align="left">2.47</td><td align="left">0.62</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">0.69</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">0.62</td><td align="left">0.32</td><td align="left">0.71</td><td align="left">1.50</td></tr><tr><td align="left">Axilla level II</td><td align="left">2.49</td><td align="left">2.03</td><td align="left">1.17</td><td align="left">1.36</td><td align="left">0.95</td><td align="left">1.32</td><td align="left">0.00</td><td align="left">1.52</td><td align="left">2.50</td><td align="left">0.80</td><td align="left">1.64</td><td align="left">1.19</td><td align="left">2.43</td><td align="left">1.53</td></tr><tr><td align="left">Axilla level III</td><td align="left">1.64</td><td align="left">0.00</td><td align="left">0.89</td><td align="left">1.91</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">0.00</td><td align="left">2.84</td><td align="left">0.82</td></tr><tr><td align="left"><italic>Axilla levels I-III combined</italic></td><td align="left">0.61</td><td align="left">0.47</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">0.17</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">Inf</td><td align="left">0.31</td><td align="left">0.08</td><td align="left">Inf</td><td align="left">0.60</td></tr><tr><td align="left">Internal mammary</td><td align="left"><bold>5.03 (2.52, 10.31)</bold></td><td align="left">2.79</td><td align="left">1.66</td><td align="left">1.64</td><td align="left">4.03</td><td align="left"><bold>6.44 (2.62, 15.60)</bold></td><td align="left"><bold>10.70 (4.08, 28.00)</bold></td><td align="left"><bold>24.40 (7.97, 78.80)</bold></td><td align="left"><bold>18.90 (6.23, 58.50)</bold></td><td align="left"><bold>8.39 (2.74, 24.80)</bold></td><td align="left"><bold>10.10 (4.54, 22.40)</bold></td><td align="left"><bold>9.41 (4.31, 20.70)</bold></td><td align="left">3.72</td><td align="left"><bold>4.35 (2.53, 7.95)</bold></td></tr><tr><td align="left">Interval</td><td align="left">5.92</td><td align="left">2.19</td><td align="left">3.80</td><td align="left">5.80</td><td align="left">3.33</td><td align="left"><bold>14.00 (3.67, 63.60)</bold></td><td align="left">8.32</td><td align="left">8.65</td><td align="left">1.97</td><td align="left">2.06</td><td align="left">2.45</td><td align="left">4.81</td><td align="left">3.73</td><td align="left">4.63</td></tr></tbody></table></table-wrap></p><p id="Par15">The most common tumour site receiving PT injections was the 2 o&#x02019;clock region (<italic>n</italic>&#x02009;=&#x02009;198), closely followed by the retroareolar 0 o&#x02019;clock region (<italic>n&#x02009;</italic>=&#x02009;108). The least common tumour sites receiving PT injections were the 7, 8, and 9 o&#x02019;clock regions (<italic>n</italic>&#x02009;=&#x02009;24, 23, 22, respectively). Overall, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows the proportion of SLNs identified in the internal mammary node field draining the entire breast was significantly higher when using PT injections compared to SA injections (0.30 versus 0.09). When analysing each breast region separately, there were nine regions with significantly higher proportions draining to the internal mammary node field when using PT injections compared to SA injections. This included the retroareolar 0 o&#x02019;clock region, and regions from 4 o&#x02019;clock through to 11 o&#x02019;clock which together encompass the lower outer, lower inner and upper inner quadrants (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The upper outer quadrant, encompassing 1, 2, 3, and 12 o&#x02019;clock regions, also had a lower drainage proportion to the internal mammary node field from SA injections, but none were statistically significant. The drainage proportion to interval nodes from PT injections was higher for all breast regions when compared with SA injections, but only significantly different for the 5 o&#x02019;clock region (0.24 versus 0.02). No other drainage proportions had a statistically significant difference between injection types.</p><p id="Par16">Odds ratios (PT odds divided by SA odds) in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> show that for the entire breast the drainage to the internal mammary node field was significantly different between injection types, with an odds ratio of 4.35 (95% CI 2.53 to 7.95). When assessing odds ratios for each breast region, the internal mammary node field had eight breast regions with significantly higher odds ratios (ranging from 5.03 to 24.40). These included the retroareolar 0 o&#x02019;clock region, and the 5 o&#x02019;clock through to 11 o&#x02019;clock regions, which also showed significant results in the proportions test (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The only difference between the two test results for the internal mammary node field was the 4 o&#x02019;clock region did not have a significant odds ratio, but the 4 o&#x02019;clock region proportion z-test results did show a significant difference between injection types. The interval node odds ratio was over 1.0 for all breast regions, but only significant for the 5 o&#x02019;clock region (14.00, 95% CI 3.67 to 63.60). No other odds ratio value was statistically significant.</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par17">This study has statistically compared the regional location of breast SLNs identified by PT versus SA injections. The analysis has included the largest number of patients from a single-centre and was further strengthened by incorporating precise anatomical localisation of both breast tumours and SLNs from SPECT/CT. No other study has incorporated tumour locations discretised into clockface breast regions or had SLNs identified in as many axillary subregions as well as including interval nodes.</p><p id="Par18">Findings showed there were no significant differences between the regional location of axillary SLNs identified by the injection types, even with multiple subregions including axillary level I (covering anterior, central, posterior, lateral, interpectoral groups), axillary level II, and axillary level III. This agrees with previous studies by Noushi et al. [<xref ref-type="bibr" rid="CR10">10</xref>], although they grouped all axillary SLNs into one region, and Uren et al. [<xref ref-type="bibr" rid="CR5">5</xref>], who did incorporate axillary subregions but did not discretise the breast into regions. Findings in this study also showed that identification of internal mammary SLNs was lower when using SA injections compared to PT injections, which was concordant with previous studies [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], and was statistically significant in all clockface breast regions except those corresponding with the upper outer quadrant. The only other breast region with significant differences between injection sites was the 5 o&#x02019;clock breast region, for identifying SLNs classified as interval nodes, which has not been reported previously. Interval nodes include intramammary and intercostal SLNs, which are often overlooked, even though they may have prognostic significance and show advanced pathological features when malignant [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par19">Recent anatomical studies of the lymphatic system in the breast confirm these findings and support PT injections being more suitable than SA injections for accurately mapping SLNs [<xref ref-type="bibr" rid="CR4">4</xref>]. Initially, SA injections were supported by historical anatomical studies that described lymphatics in the breast parenchyma converging to the subareolar plexus and then switching to the lymphatic vessels running to the axillary lymph nodes [<xref ref-type="bibr" rid="CR20">20</xref>]. However, publications from the same group also depicted the lymphatic vessels in the upper torso connecting to the axillary lymph nodes but the relationship with these lymphatic vessels from two different origins was not clarified [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par20">Anatomical studies using a microinjection technique to visualise lymphatic vessels recently reported that lymphatics in the breast drain to the lymph nodes via three different lymphatic pathways [<xref ref-type="bibr" rid="CR4">4</xref>]. This includes lymphatic vessels originating from the upper torso, lymphatic vessels originating from the areola, and perforating lymphatic vessels running with the perforating arteries to the internal mammary artery and connecting to the internal mammary lymph nodes (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). This explains why PT injections are more likely to identify the internal mammary lymph nodes and may identify different SLNs from SA injections.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Lymphatic anatomy of the breast: <bold>A</bold> lymphatic vessels originating from the upper torso, <bold>B</bold> a lymphatic vessel originating from the areola and <bold>C</bold> perforating lymphatic vessels connecting to the internal mammary lymph nodes</p></caption><graphic xlink:href="10549_2024_7491_Fig3_HTML" id="MO3"/></fig></p><p id="Par21">Metastatic involvement of internal mammary nodes is known to be higher in patients with medial tumours and positive axillary SLNs [<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, the metastatic status of internal mammary nodes is included in the American Joint Committee on Cancer staging criteria where it has prognostic importance similar to axillary node involvement [<xref ref-type="bibr" rid="CR22">22</xref>] and undiagnosed internal mammary metastasis has been associated with significantly worse survival outcomes [<xref ref-type="bibr" rid="CR23">23</xref>]. Therefore, ensuring accurate detection of SLNs in the internal mammary node field would logically be important for informing and optimising patient treatment, including surgery and radiation therapy options. If it is too risky to biopsy an internal mammary sentinel node, then the staging process will be incomplete and regional node irradiation to the internal mammary nodes should be considered. A recent review article by Lenihan et al. [<xref ref-type="bibr" rid="CR24">24</xref>] reported four clinical trials which considered adjuvant internal mammary node irradiation when axillary nodes were positive. Overall, trial findings supported regional nodal irradiation including internal mammary nodes, with one Danish trial confirming it provided a survival advantage [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par22">PT injections carried out in the retroareolar (0 o&#x02019;clock) region and SA injection sites are both located behind the areola. However, PT injections are located at the depth of the tumour, which is deeper than SA injections located less than 0.5&#x000a0;cm from the skin surface. Hence, the statistical comparisons between retroareolar PT injections and SA injections suggest that deeper injections increase the drainage proportion to internal mammary node fields. These results contradict Noushi et al. [<xref ref-type="bibr" rid="CR10">10</xref>], who found that the depth of PT injection did not have a significant effect on discordance, albeit with a smaller number of patients. The PT injection depth was not recorded in this study, and comparisons between patients may be difficult due to differences in breast shape and deformation. Further research to investigate the effect of injection depth on lymphatic drainage patterns is therefore warranted.</p><p id="Par23">There are some limitations to this study, including the low number of patients with drainage in some breast regions, which meant the two-proportion z-test could not be carried out for all node fields. Additionally, SA injections were administered when patients were scheduled for a prophylactic mastectomy, had DCIS, or had tumours or DCIS not visualised on ultrasound. Consequently, SA patients were typically at a comparatively earlier cancer stage and were younger than PT patients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) which may impact lymphatic drainage, as studies by Kawase et al. [<xref ref-type="bibr" rid="CR26">26</xref>], Kong et al. [<xref ref-type="bibr" rid="CR27">27</xref>], and Lukesova et al. [<xref ref-type="bibr" rid="CR28">28</xref>] have shown that younger patients have a higher likelihood of having internal mammary SLNs. Controlling for the effects of age may increase the difference between injection types for internal mammary drainage, but it was not carried out in this study. Furthermore, the number of injections and hence the volume of tracer varied between patients in both PT and SA groups. An increase in injection volume likely increases the drainage observed, so future analyses which take this into account would allow for greater confidence in the results.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par24">Lymphatic drainage from the breast to SLNs in the internal mammary node field is significantly more common when using PT injections than SA injections, in all regions of the breast excluding the upper outer quadrant. Significant differences persisted when restricting comparisons to retroareolar PT injections, suggesting injection depth is a factor impacting lymphatic drainage. There were no significant differences in lymphatic drainage to axillary subregions between the injection types. These results support the use of PT injections for accurate identification of breast SLNs, especially extra-axillary SLNs, and help improve understanding of breast lymphatic drainage patterns.</p></sec><sec id="Sec9" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10549_2024_7491_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 146 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>HMR conceptualised the study and obtained funding. JS performed the statistical analysis and wrote the first draft of the manuscript. HMR, TDJD, and CW provided study supervision and contributed to methodology development. DKVC provided data and contributed to result interpretation. HS contributed to result interpretation and created the figures. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by CAUL and its Member Institutions. HMR is funded by a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data analysed in this study are not publicly available due to ethical requirements but are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par25">All authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par26">Ethics approval was obtained from Melanoma Institute Australia Research Committee (MIA2020/293) and University of Auckland Human Participants Ethics Committee (UAHPEC 024229).</p></notes><notes id="FPar3"><title>Informed consent</title><p id="Par27">This was a retrospective study, with ethics committee review confirming that informed consent was not required. All patient identifiers were removed from data prior to analysis.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="book"><person-group person-group-type="author"><name><surname>Pereira Arias-Bouda</surname><given-names>LM</given-names></name><name><surname>Vidal-Sicart</surname><given-names>S</given-names></name><name><surname>Vald&#x000e9;s Olmos</surname><given-names>RA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mariani</surname><given-names>G</given-names></name><name><surname>Vidal-Sicart</surname><given-names>S</given-names></name><name><surname>Vald&#x000e9;s Olmos</surname><given-names>RA</given-names></name></person-group><article-title>Preoperative and intraoperative lymphatic mapping for radioguided sentinel lymph node biopsy in breast cancer</article-title><source>Atlas of lymphoscintigraphy and sentinel node mapping a pictorial case-based approach</source><year>2020</year><publisher-loc>Cham</publisher-loc><publisher-name>springer</publisher-name><fpage>185</fpage><lpage>217</lpage></element-citation><mixed-citation id="mc-CR1" publication-type="book">Pereira Arias-Bouda LM, Vidal-Sicart S, Vald&#x000e9;s Olmos RA (2020) Preoperative and intraoperative lymphatic mapping for radioguided sentinel lymph node biopsy in breast cancer. In: Mariani G, Vidal-Sicart S, Vald&#x000e9;s Olmos RA (eds) Atlas of lymphoscintigraphy and sentinel node mapping a pictorial case-based approach. springer, Cham, pp 185&#x02013;217. 10.1007/978-3-030-45296-4_9</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Purushotham</surname><given-names>AD</given-names></name><name><surname>Horgan</surname><given-names>K</given-names></name><name><surname>Klaase</surname><given-names>JM</given-names></name><name><surname>Douek</surname><given-names>M</given-names></name></person-group><article-title>Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer&#x02019;</article-title><source>Br J Surg</source><year>2015</year><pub-id pub-id-type="doi">10.1002/bjs.9673</pub-id><pub-id pub-id-type="pmid">26663252</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ahmed M, Purushotham AD, Horgan K, Klaase JM, Douek M (2015) Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer&#x02019;. Br J Surg. 10.1002/bjs.9673<pub-id pub-id-type="pmid">26663252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Vald&#x000e9;s Olmos</surname><given-names>RA</given-names></name><name><surname>Vidal-Sicart</surname><given-names>S</given-names></name></person-group><article-title>Nuclear medicine contribution to precision surgery in breast cancer</article-title><source>Revista Espa&#x000f1;ola de Medicina Nuclear e Imagen Molecular</source><year>2023</year><volume>42</volume><issue>5</issue><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.remnie.2023.07.001</pub-id><pub-id pub-id-type="pmid">37422262</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Vald&#x000e9;s Olmos RA, Vidal-Sicart S (2023) Nuclear medicine contribution to precision surgery in breast cancer. Revista Espa&#x000f1;ola de Medicina Nuclear e Imagen Molecular 42(5):343&#x02013;351. 10.1016/j.remnie.2023.07.001<pub-id pub-id-type="pmid">37422262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="book"><person-group person-group-type="author"><name><surname>Sappey</surname><given-names>Marie Philibert Constant</given-names></name></person-group><source>Anatomie, physiologie, pathologie des vaisseaux lymphatiques consid&#x000e9;r&#x000e9;s chez l&#x02019;homme et les vert&#x000e9;br&#x000e9;s</source><year>1874</year><publisher-loc>Paris</publisher-loc><publisher-name>Adrien Delahaye</publisher-name></element-citation><mixed-citation id="mc-CR4" publication-type="book">Sappey MPC (1874) Anatomie, physiologie, pathologie des vaisseaux lymphatiques consid&#x000e9;r&#x000e9;s chez l&#x02019;homme et les vert&#x000e9;br&#x000e9;s. Adrien Delahaye, Paris</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Suami</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>WR</given-names></name><name><surname>Mann</surname><given-names>GB</given-names></name><name><surname>Taylor</surname><given-names>GI</given-names></name></person-group><article-title>The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study</article-title><source>Ann Surg Oncol</source><year>2008</year><volume>15</volume><issue>3</issue><fpage>863</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1245/s10434-007-9709-9</pub-id><pub-id pub-id-type="pmid">18043970</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Suami H, Pan WR, Mann GB, Taylor GI (2008) The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol 15(3):863&#x02013;871. 10.1245/s10434-007-9709-9<pub-id pub-id-type="pmid">18043970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Uren</surname><given-names>RF</given-names></name><etal/></person-group><article-title>SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla</article-title><source>Breast</source><year>2012</year><volume>21</volume><issue>4</issue><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2011.11.007</pub-id><pub-id pub-id-type="pmid">22153573</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Uren RF et al (2012) SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. Breast 21(4):480&#x02013;486. 10.1016/j.breast.2011.11.007<pub-id pub-id-type="pmid">22153573</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Blumgart</surname><given-names>EI</given-names></name><name><surname>Uren</surname><given-names>RF</given-names></name><name><surname>Nielsen</surname><given-names>PMF</given-names></name><name><surname>Nash</surname><given-names>MP</given-names></name><name><surname>Reynolds</surname><given-names>HM</given-names></name></person-group><article-title>Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2011</year><volume>130</volume><issue>2</issue><fpage>699</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1007/s10549-011-1737-2</pub-id><pub-id pub-id-type="pmid">21850393</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Blumgart EI, Uren RF, Nielsen PMF, Nash MP, Reynolds HM (2011) Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer. Breast Cancer Res Treat 130(2):699&#x02013;705. 10.1007/s10549-011-1737-2<pub-id pub-id-type="pmid">21850393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Situ</surname><given-names>J</given-names></name><etal/></person-group><article-title>An interactive 3D atlas of sentinel lymph nodes in breast cancer developed using SPECT/CT</article-title><source>Cancer Imaging</source><year>2024</year><pub-id pub-id-type="doi">10.1186/s40644-024-00738-z</pub-id><pub-id pub-id-type="pmid">39080795</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Situ J et al (2024) An interactive 3D atlas of sentinel lymph nodes in breast cancer developed using SPECT/CT. Cancer Imaging. 10.1186/s40644-024-00738-z<pub-id pub-id-type="pmid">39080795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>R</given-names></name><name><surname>Asadi</surname><given-names>M</given-names></name><name><surname>Treglia</surname><given-names>G</given-names></name><name><surname>Zakavi</surname><given-names>SR</given-names></name><name><surname>Fattahi</surname><given-names>A</given-names></name><name><surname>Krag</surname><given-names>DN</given-names></name></person-group><article-title>Axillary concordance between superficial and deep sentinel node mapping material injections in breast cancer patients: systematic review and meta-analysis of the literature</article-title><source>Breast Cancer Res Treat</source><year>2014</year><pub-id pub-id-type="doi">10.1007/s10549-014-2866-1</pub-id><pub-id pub-id-type="pmid">24878987</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sadeghi R, Asadi M, Treglia G, Zakavi SR, Fattahi A, Krag DN (2014) Axillary concordance between superficial and deep sentinel node mapping material injections in breast cancer patients: systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 10.1007/s10549-014-2866-1<pub-id pub-id-type="pmid">24878987</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Spillane</surname><given-names>AJ</given-names></name><name><surname>Noushi</surname><given-names>F</given-names></name><name><surname>Cooper</surname><given-names>RA</given-names></name><name><surname>Gebski</surname><given-names>V</given-names></name><name><surname>Uren</surname><given-names>RF</given-names></name></person-group><article-title>High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer</article-title><source>Ann Oncol</source><year>2009</year><pub-id pub-id-type="doi">10.1093/annonc/mdn725</pub-id><pub-id pub-id-type="pmid">19153113</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Spillane AJ, Noushi F, Cooper RA, Gebski V, Uren RF (2009) High-resolution lymphoscintigraphy is essential for recognition of the significance of internal mammary nodes in breast cancer. Ann Oncol. 10.1093/annonc/mdn725<pub-id pub-id-type="pmid">19153113</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Noushi</surname><given-names>F</given-names></name><etal/></person-group><article-title>High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy</article-title><source>Eur J Surg Oncol</source><year>2013</year><volume>39</volume><issue>10</issue><fpage>1053</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2013.06.006</pub-id><pub-id pub-id-type="pmid">23871572</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Noushi F et al (2013) High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy. Eur J Surg Oncol 39(10):1053&#x02013;1060. 10.1016/j.ejso.2013.06.006<pub-id pub-id-type="pmid">23871572</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Freebody</surname><given-names>JA</given-names></name><name><surname>Fernando</surname><given-names>S</given-names></name><name><surname>Rossleigh</surname><given-names>M</given-names></name></person-group><article-title>Triple-site radiotracer application in breast lymphoscintigraphy and sentinel node discordance</article-title><source>World J Nucl Med</source><year>2019</year><volume>18</volume><issue>02</issue><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.4103/wjnm.wjnm_32_18</pub-id><pub-id pub-id-type="pmid">31040742</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Freebody JA, Fernando S, Rossleigh M (2019) Triple-site radiotracer application in breast lymphoscintigraphy and sentinel node discordance. World J Nucl Med 18(02):127&#x02013;131. 10.4103/wjnm.wjnm_32_18<pub-id pub-id-type="pmid">31040742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio</surname><given-names>IT</given-names></name><etal/></person-group><article-title>The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer</article-title><source>Eur J Surg Oncol</source><year>2015</year><volume>41</volume><issue>1</issue><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2014.11.006</pub-id><pub-id pub-id-type="pmid">25466980</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Rubio IT et al (2015) The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. Eur J Surg Oncol 41(1):46&#x02013;51. 10.1016/j.ejso.2014.11.006<pub-id pub-id-type="pmid">25466980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Zetterlund</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impact of previous surgery on sentinel lymph node mapping: Hybrid SPECT/CT before and after a unilateral diagnostic breast excision</article-title><source>Breast</source><year>2016</year><volume>30</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2016.08.006</pub-id><pub-id pub-id-type="pmid">27597384</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zetterlund L et al (2016) Impact of previous surgery on sentinel lymph node mapping: Hybrid SPECT/CT before and after a unilateral diagnostic breast excision. Breast 30:32&#x02013;38. 10.1016/j.breast.2016.08.006<pub-id pub-id-type="pmid">27597384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>WC</given-names></name><name><surname>An</surname><given-names>CX</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group><article-title>Comparative research on 99mTc-Rituximab and 99mTc-sulfur colloid in sentinel lymph node imaging of breast cancer&#x02019;</article-title><source>BMC Cancer</source><year>2019</year><pub-id pub-id-type="doi">10.1186/s12885-019-6197-9</pub-id><pub-id pub-id-type="pmid">31888612</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhang JJ, Zhang WC, An CX, Li XM, Ma L (2019) Comparative research on 99mTc-Rituximab and 99mTc-sulfur colloid in sentinel lymph node imaging of breast cancer&#x02019;. BMC Cancer. 10.1186/s12885-019-6197-9<pub-id pub-id-type="pmid">31888612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">McDonald JH (2014) Small numbers in chi-square and G&#x02013;tests, In: Handbook of biological statistics, 3rd ed., Sparky House Publishing, Baltimore, pp 86&#x02013;89. <ext-link ext-link-type="uri" xlink:href="https://www.biostathandbook.com/HandbookBioStatThird.pdf">https://www.biostathandbook.com/HandbookBioStatThird.pdf</ext-link></mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>RA</given-names></name></person-group><article-title>When to use the bonferroni correction</article-title><source>Ophthalmic Physiol Optic</source><year>2014</year><pub-id pub-id-type="doi">10.1111/opo.12131</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Armstrong RA (2014) When to use the bonferroni correction. Ophthalmic Physiol Optic. 10.1111/opo.12131</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">R Core Team, (2024) R: a language and environment for statistical computing, 2021, R foundation for statistical computing, Vienna, Austria. <ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link> Accessed Jul 09 2024</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Maza</surname><given-names>S</given-names></name><etal/></person-group><article-title>Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: Preliminary results of a prospective intra-individual comparative study</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2003</year><volume>30</volume><issue>5</issue><fpage>651</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1007/s00259-003-1128-y</pub-id><pub-id pub-id-type="pmid">12612811</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Maza S et al (2003) Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: Preliminary results of a prospective intra-individual comparative study. Eur J Nucl Med Mol Imaging 30(5):651&#x02013;656. 10.1007/s00259-003-1128-y<pub-id pub-id-type="pmid">12612811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hashem</surname><given-names>T</given-names></name><name><surname>Abdelmoez</surname><given-names>A</given-names></name><name><surname>Rozeka</surname><given-names>AM</given-names></name><name><surname>Abdelazeem</surname><given-names>H</given-names></name></person-group><article-title>Intra-mammary lymph nodes, an overlooked breast cancer prognostic tool?</article-title><source>World J Surg Oncol</source><year>2021</year><pub-id pub-id-type="doi">10.1186/s12957-021-02219-0</pub-id><pub-id pub-id-type="pmid">33849561</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hashem T, Abdelmoez A, Rozeka AM, Abdelazeem H (2021) Intra-mammary lymph nodes, an overlooked breast cancer prognostic tool? World J Surg Oncol. 10.1186/s12957-021-02219-0<pub-id pub-id-type="pmid">33849561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="book"><person-group person-group-type="author"><name><surname>Delamere</surname><given-names>G</given-names></name><name><surname>Poirier</surname><given-names>P</given-names></name><name><surname>Cuneo</surname><given-names>B</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Charpy</surname><given-names>P</given-names></name></person-group><article-title>The lymphatics</article-title><source>A treatise of human anatomy</source><year>1903</year><publisher-loc>Westminster</publisher-loc><publisher-name>Archibald Constable</publisher-name></element-citation><mixed-citation id="mc-CR21" publication-type="book">Delamere G, Poirier P, Cuneo B (1903) The lymphatics. In: Charpy P (ed) A treatise of human anatomy. Archibald Constable, Westminster</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Manca</surname><given-names>G</given-names></name><etal/></person-group><article-title>Sentinel lymph node mapping in breast cancer: a critical reappraisal of the internal mammary chain issue</article-title><source>Q J Nucl Med Mol Imaging</source><year>2014</year><volume>58</volume><issue>2</issue><fpage>114</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">24835288</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Manca G et al (2014) Sentinel lymph node mapping in breast cancer: a critical reappraisal of the internal mammary chain issue. Q J Nucl Med Mol Imaging 58(2):114&#x02013;126<pub-id pub-id-type="pmid">24835288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Teichgraeber</surname><given-names>DC</given-names></name><name><surname>Guirguis</surname><given-names>MS</given-names></name><name><surname>Whitman</surname><given-names>GJ</given-names></name></person-group><article-title>Breast cancer staging: updates in the AJCC cancer staging manual 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging</article-title><source>Am J Roentgenol</source><year>2021</year><pub-id pub-id-type="doi">10.2214/AJR.20.25223</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Teichgraeber DC, Guirguis MS, Whitman GJ (2021) Breast cancer staging: updates in the AJCC cancer staging manual 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. Am J Roentgenol. 10.2214/AJR.20.25223</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Noushi</surname><given-names>F</given-names></name><name><surname>Spillane</surname><given-names>AJ</given-names></name><name><surname>Uren</surname><given-names>RF</given-names></name><name><surname>Gebski</surname><given-names>V</given-names></name></person-group><article-title>Internal mammary node metastasis in breast cancer: predictive models to determine status &#x00026; management algorithms</article-title><source>Eur J Surg Oncol</source><year>2010</year><volume>36</volume><issue>1</issue><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2009.09.006</pub-id><pub-id pub-id-type="pmid">19846271</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Noushi F, Spillane AJ, Uren RF, Gebski V (2010) Internal mammary node metastasis in breast cancer: predictive models to determine status &#x00026; management algorithms. Eur J Surg Oncol 36(1):16&#x02013;22. 10.1016/j.ejso.2009.09.006<pub-id pub-id-type="pmid">19846271</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Lenihan</surname><given-names>J</given-names></name><name><surname>Rangaswamy</surname><given-names>G</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name></person-group><article-title>The role of radiotherapy in the management of nodal disease in breast cancer</article-title><source>Rep Pract Oncol Radiother</source><year>2022</year><volume>27</volume><issue>2</issue><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.5603/rPOr.a2022.0037</pub-id><pub-id pub-id-type="pmid">36299373</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lenihan J, Rangaswamy G, Faul C (2022) The role of radiotherapy in the management of nodal disease in breast cancer. Rep Pract Oncol Radiother 27(2):331&#x02013;343. 10.5603/rPOr.a2022.0037<pub-id pub-id-type="pmid">36299373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Thorsen</surname><given-names>L</given-names></name><etal/></person-group><article-title>DBCG radiotherapy committee. internal mammary node irradiation in patients with node-positive early breast cancer: fifteen-year results from the danish breast cancer group internal mammary node study</article-title><source>J Clin Oncol</source><year>2022</year><volume>40</volume><issue>36</issue><fpage>4198</fpage><lpage>4206</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.00044</pub-id><pub-id pub-id-type="pmid">35394824</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Thorsen L et al (2022) DBCG radiotherapy committee. internal mammary node irradiation in patients with node-positive early breast cancer: fifteen-year results from the danish breast cancer group internal mammary node study. J Clin Oncol 40(36):4198&#x02013;4206<pub-id pub-id-type="pmid">35394824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kawase</surname><given-names>K</given-names></name><etal/></person-group><article-title>Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer</article-title><source>J Am Coll Surg</source><year>2006</year><volume>203</volume><issue>1</issue><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2006.03.015</pub-id><pub-id pub-id-type="pmid">16798488</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kawase K et al (2006) Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg 203(1):64&#x02013;72. 10.1016/j.jamcollsurg.2006.03.015<pub-id pub-id-type="pmid">16798488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage i to III breast cancer&#x02019;</article-title><source>Cancer</source><year>2012</year><pub-id pub-id-type="doi">10.1002/cncr.27564</pub-id><pub-id pub-id-type="pmid">23303625</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kong AL et al (2012) Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage i to III breast cancer&#x02019;. Cancer. 10.1002/cncr.27564<pub-id pub-id-type="pmid">23303625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Lukesova</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prognostic influence of internal mammary node drainage in patients with early-stage breast cancer</article-title><source>Anticancer Res</source><year>2016</year><volume>36</volume><issue>12</issue><fpage>6641</fpage><lpage>6646</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11272</pub-id><pub-id pub-id-type="pmid">27919996</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Lukesova L et al (2016) Prognostic influence of internal mammary node drainage in patients with early-stage breast cancer. Anticancer Res 36(12):6641&#x02013;6646. 10.21873/anticanres.11272<pub-id pub-id-type="pmid">27919996</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>